12:00 AM
Jul 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

KS-6H9Chi: Began Phase I trial

(KSB licensing deal, B4)

KS Biomedix Holdings plc (LSE:KSB), London, U.K.
Product: KS-6H9Chi
Business: Cancer

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >